| Literature DB >> 29075985 |
Rivka R Colen1,2, Takeo Fujii3, Mehmet Asim Bilen4, Aikaterini Kotrotsou5,4, Srishti Abrol5, Kenneth R Hess6, Joud Hajjar7, Maria E Suarez-Almazor8, Anas Alshawa3, David S Hong3, Dunia Giniebra-Camejo4, Bettzy Stephen3, Vivek Subbiah3, Ajay Sheshadri9, Tito Mendoza10, Siqing Fu3, Padmanee Sharma11, Funda Meric-Bernstam3, Aung Naing12.
Abstract
We present the first reported work that explores the potential of radiomics to predict patients who are at risk for developing immunotherapy-induced pneumonitis. Despite promising results with immunotherapies, immune-related adverse events (irAEs) are challenging. Although less common, pneumonitis is a potentially fatal irAE. Thus, early detection is critical for improving treatment outcomes; an urgent need to identify biomarkers that predict patients at risk for pneumonitis exists. Radiomics, an emerging field, is the automated extraction of high fidelity, high-dimensional imaging features from standard medical images and allows for comprehensive visualization and characterization of the tissue of interest and corresponding microenvironment. In this pilot study, we sought to determine whether radiomics has the potential to predict development of pneumonitis. We performed radiomic analyses using baseline chest computed tomography images of patients who did (N = 2) and did not (N = 30) develop immunotherapy-induced pneumonitis. We extracted 1860 radiomic features in each patient. Maximum relevance and minimum redundancy feature selection method, anomaly detection algorithm, and leave-one-out cross-validation identified radiomic features that were significantly different and predicted subsequent immunotherapy-induced pneumonitis (accuracy, 100% [p = 0.0033]). This study suggests that radiomic features can classify and predict those patients at baseline who will subsequently develop immunotherapy-induced pneumonitis, further enabling risk-stratification that will ultimately lead to better treatment outcomes.Entities:
Keywords: Immune-related adverse event; Immunotherapy; Pneumonitis; Radiomics
Mesh:
Substances:
Year: 2017 PMID: 29075985 PMCID: PMC5924418 DOI: 10.1007/s10637-017-0524-2
Source DB: PubMed Journal: Invest New Drugs ISSN: 0167-6997 Impact factor: 3.850